Brought to you by 
Sankyo-Parke-Davis to sell GelTex drug in US
Dec 1999
Executive Summary
In an effort to boost its US presence, Sankyo licensed exclusive marketing rights here to GelTex's (developing polymer-based drugs that bind and eliminate targeted substances in the intestines) Welchol (colesevelam hydrochloride), a cholesterol-lowering drug awaiting FDA approval. It also optioned worldwide rights to a second-generation version of the drug that GelTex says is twice as potent, GT102-279, which is in Phase II trials.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sankyo-Parke-Davis to sell GelTex drug in US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice